NASDAQ:ADXS - Advaxis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.3799 -0.01 (-2.56 %)
(As of 12/10/2018 06:14 AM ET)
Previous Close$0.3941
Today's Range$0.3776 - $0.4078
52-Week Range$0.38 - $3.58
Volume320,475 shs
Average Volume436,889 shs
Market Capitalization$20.07 million
P/E Ratio-0.16
Dividend YieldN/A
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:ADXS
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio3.95
Quick Ratio3.95


Trailing P/E Ratio-0.16
Forward P/E Ratio-0.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.03 million
Price / Sales1.67
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.32 per share
Price / Book0.29


EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-1,062.68%
Return on Equity-165.23%
Return on Assets-91.46%


Outstanding Shares52,830,000
Market Cap$20.07 million

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) announced its earnings results on Monday, March, 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.06. The biotechnology company had revenue of $2.06 million for the quarter, compared to analysts' expectations of $3.03 million. Advaxis had a negative return on equity of 165.23% and a negative net margin of 1,062.68%. View Advaxis' Earnings History.

When is Advaxis' next earnings date?

Advaxis is scheduled to release their next quarterly earnings announcement on Wednesday, December 19th 2018. View Earnings Estimates for Advaxis.

What price target have analysts set for ADXS?

3 brokerages have issued 12-month price targets for Advaxis' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Advaxis' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 689.7% from the stock's current price. View Analyst Price Targets for Advaxis.

What is the consensus analysts' recommendation for Advaxis?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Advaxis.

Has Advaxis been receiving favorable news coverage?

News articles about ADXS stock have been trending very positive on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Advaxis earned a daily sentiment score of 3.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the near future.

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 69)
  • Mr. Kenneth A. Berlin, Pres, CEO and Director (Age 54)
  • Ms. Molly Henderson CPA, MBA, Exec. VP & CFO (Age 47)
  • Mr. Mayo Pujols, Sr. VP of Technical Operations

Who are Advaxis' major shareholders?

Advaxis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.26%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

Which major investors are buying Advaxis stock?

ADXS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.3799.

How big of a company is Advaxis?

Advaxis has a market capitalization of $20.07 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

MarketBeat Community Rating for Advaxis (NASDAQ ADXS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel